RADNOR, PA — Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) has fortified its intellectual property holdings with the United States Patent and Trademark Office’s issuance of a new patent for ZTALMY® (ganaxolone) oral titration regimens. This patent, numbered 12,115,169, extends through September 2042 and encompasses treatments for various epilepsy disorders such as CDKL5 deficiency disorder, tuberous sclerosis complex (TSC), and Lennox-Gastaut syndrome (LGS).
The addition of this patent strengthens Marinus’ strategic positioning in the development and commercialization of ganaxolone. According to Scott Braunstein, M.D., Chairman and CEO of Marinus, this enhancement of their IP estate is backed by extensive research and clinical data that underscore the unique pharmacological profile and dosing efficacy of ganaxolone.
The newly patented titration regimens distinguish themselves from previous methods, potentially offering improved tolerability and compliance for patients. This innovation is expected to deliver tangible benefits in managing epilepsy disorders, contributing to better patient outcomes by enhancing the effectiveness and patient experience of the treatment.
With this patent, Marinus Pharmaceuticals not only secures a competitive edge in the field of epilepsy treatment but also reinforces its commitment to addressing high unmet medical needs in neurological disorders. The company continues to focus on advancing therapeutic options that can significantly impact the lives of patients with challenging epilepsy conditions.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.